◀ Back to CDKN1A

CDKN1A — ESR2

Text-mined interactions from Literome

Gartel et al., Proc Natl Acad Sci U S A 2001 : We found that activation of a Myc-estrogen receptor fusion protein by 4-hydroxytamoxifen in mouse cells resulted in suppression of endogenous p21 transcription
Lazennec et al., Endocrinology 2001 (Breast Neoplasms...) : ER beta and ER alpha induced the expression of several endogenous genes such as pS2, TGF alpha, or the cyclin kinase inhibitor p21 but, in contrast to ER alpha, ER beta was unable to regulate c-myc proto-oncogene expression
Paruthiyil et al., Cancer Res 2004 (Breast Neoplasms) : ERbeta inhibits proliferation by repressing c-myc, cyclin D1, and cyclin A gene transcription, and increasing the expression of p21 ( Cip1 ) and p27 ( Kip1 ), which leads to a G ( 2 ) cell cycle arrest
Hou et al., Oncogene 2004 (Breast Neoplasms...) : In ERbeta transfected MDA-MB-435 xenografts, ERbeta caused significant reduction in p21 protein levels
Zhao et al., J Cell Biochem 2004 (Breast Neoplasms) : Elevated expression of the estrogen receptor prevents the down-regulation of p21Waf1/Cip1 in hormone dependent breast cancer cells
Matsumura et al., Anticancer Res 2008 (Prostatic Neoplasms) : ERbeta is involved in genistein induced expression of p21 in PC-3 cells
Pinton et al., Cancer Res 2009 (Disease Progression...) : Moreover, studies in vitro confirmed that treatment with 17beta-estradiol led to an ERbeta mediated inhibition of malignant mesothelioma cell proliferation as well as p21 ( CIP1 ) and p27 ( KIP1 ) up-regulation
Hartman et al., Cancer Res 2009 (Colonic Neoplasms) : Furthermore, the c-Myc target gene p21 ( ( Waf1/Cip1 ) ) was induced and Cdc25A was reduced by ERbeta at the transcriptional level